CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 51 enrolled
Drug / intervention
Insulin Icodecdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05823948
NCT05823948Phase 3Completed

A Study to Evaluate Flash Glucose Monitoring Based Titration of Once-weekly Insulin Icodec in Insulin-naïve Participants With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Apr 21, 2023·Updated Apr 30, 2026

In Brief

A Phase 3 clinical trial evaluating Insulin Icodec for Diabetes Mellitus, Type 2. Completed, enrolled 51 participants across 20 sites.

Detailed Summary

This study looks at how a person with type 2 diabetes can be treated with insulin icodec and a flash glucose monitor (a small sensor inserted under the skin to measure blood sugar all the time). The study will look at how well insulin icodec controls blood sugar when used in combination with a flash glucose monitor. Participants will get insulin icodec that they have to inject once a week on the same day of the week. The insulin will be injected with a needle in a skin fold in the thigh, upper arm, or stomach. The study will last for about 8 months. Participants will have to wear a flash glucose monitor throughout the study. This is a sensor that fits on arm. Participants will be asked to use a commercially available app called LibreView to allow team to view flash glucose monitor data. Participants will get a study phone to scan the flash glucose monitor 4 times daily and they will be able to see all of the flash glucose monitor data during the study. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedApr 21, 2023
Enrollment StartApr 11, 2023
Primary CompletionMar 6, 2024
Study CompletionApr 11, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.2 years ago

Interventions

Insulin Icodecdrug

Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.